Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : COMPUTERIZED THERMAL IMAGING (COII)- research only -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (96)	3/13/1999 11:00:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 256

CTI SUBSIDIARY EXPANDS CLINICAL TRIALS; Addition of St. Agnes Hospital in Baltimore Accelerates Submission to FDA March 12, 1999 12:10 PM OGDEN, Utah, March 12 /PRNewswire/ -- Thermal Medical Imaging, Inc. (TMI), an 80% owned subsidiary of Computerized Thermal Imaging, Inc. (CTI) COII , announced today that St. Agnes Hospital in Baltimore has become a clinical site for trials of TMI's proprietary breast imaging system. St. Agnes Hospital joins USC/Norris Cancer Center in Los Angeles, Mt. Sinai Medical Center in Miami Beach and Providence Hospital in Washington D.C. as clinical trial sites. David A. Packer, president of both CTI and TMI, stated, "The addition of St. Agnes Hospital as a clinical trial site should further increase the flow of patients, which in turn should help to accelerate submission of data to the FDA. Our number one objective is to generate clinical data as quickly and efficiently as possible so that we will be able to bring this product to market and help to reduce the number of unnecessary breast biopsies." The clinical trials are designed to test the efficacy of the computerized thermal imaging system as an adjunctive procedure to diagnostic mammogram and/or clinical breast examination. The system is intended to assist physicians in differentiating malignant from benign breast abnormalities prior to biopsy. Preliminary results from pilot studies of the system indicate that the system may be useful as an adjunctive procedure to current examinations, with the potential to decrease benign biopsies by 38%. The system employs a thermal sensing device coupled with a specialized computer algorithm providing quantitative diagnostic information. The technique is painless, involves no compression and takes less than fifteen minutes to perform. St. Agnes Hospital in Baltimore, a member of the Daughters of Charity National Health System, has a very well respected Women's Health Center/Comprehensive Breast Center. Enrollment for the TMI clinical trials will take place through the Women's Health Center. Patients are eligible to participate in the study if they have a suspicious breast mass and are scheduled to undergo core needle or surgical biopsy. Prospective patients in the Baltimore area who would like additional information may contact Gail Conaway, Clinical Research Director at 410-368-8620. Computerized Thermal Imaging, Inc. develops and deploys thermal imaging and associated technologies for use in the enhancement of medical screening, diagnosis and patient management. More information about CTI can be found on the Internet at www.cti-net.com or by calling CTI Public Affairs at (801) 776-4700. Except for historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In addition to the factors set forth above, other important factors that could cause actual results to differ materially include, but are not limited to technical risks associated with new technology development, government regulatory approvals or continued working capital. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings. Copies of these filings may be obtained by contacting the Company or the SEC. SOURCE Computerized Thermal Imaging, Inc

To: chirodoc who wrote (96)	3/14/1999 11:10:00 AM
From: chirodoc	Read Replies (2) \| Respond to of 256

NERVES GET INFLAMED IN NEUROLOGICAL PATHOLOGY THIS INFLAMMATION IS ONE THING THAT HAPPENS IN BACK PAIN BUT NOT IN FRAUD (HINT) Vasc Med 1998;3(3):207-14 Reflex sympathetic dystrophy: facts and hypotheses. Kurvers HA Department of Surgery of the University Hospital Maastricht, Cardiovascular Research Institute, The Netherlands. [Medline record in process] Reflex sympathetic dystrophy (RSD) syndrome has been recognized clinically for many years. It is most often initiated by trauma to a nerve, neural plexus, or soft tissue. Diagnostic criteria are the presence of regional pain and other sensory changes following a noxious event. The pain is associated with changes in skin colour, skin temperature, abnormal sweating, oedema, and sometimes motor abnormalities. The clinical course is commonly divided into three stages: first (acute or hyperaemic), second (dystrophic or ischaemic), and third (atrophic) stage. The diagnosis is primarily clinical, but roentgenography, scintigraphy, thermography, electromyography and assessment of nerve conduction velocity can help to confirm the diagnosis. Although a wide variety of treatments have been recommended, the only therapies found to be effective in large studies aim at interfering with the activity of the sympathetic nervous system. To this end, efferent sympathetic nerve activity can be interrupted surgically or chemically. Alternatively, adrenoceptor blockers may be used to relieve pain. Numerous theories have been proposed to explain the pathophysiology. Sympathetic dysfunction, which often has been purported to play a pivotal role in RSD, has been suggested to consist of an increased rate of efferent sympathetic nerve impulses towards the involved extremity induced by increased afferent activity. However, the results of several experimental studies suggest that sympathetic dysfunction consists of supersensitivity to catecholamines induced by (partial) autonomic denervation. Besides, it has been suggested that excitation of sensory nerve fibres at axonal level causes release of neuropeptides at the peripheral endings of these fibres. These neuropeptides may induce vasodilation, increase vascular permeability, and excite surrounding sensory nerve fibres -- a phenomenon referred to as neurogenic inflammation. At the level of the central nervous system, it has been suggested that the increased input from peripheral nociceptors alters the central processing mechanisms.